Results 21 to 30 of about 53,097 (209)

Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

Frontiers in Pharmacology, 2019
Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters ...
Yi Qian, Lu-Ning Sun, Yang-Jie Liu, Qiang Zhang, Jiang-Hao Xu, Zeng-Qing Ma, Xue-Hui Zhang, Hao Xu, Yong-Qing Wang, Yong-Qing Wang   +9 more
doaj   +1 more source

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor

Cells, 2020
Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST)
Wen-Kuan Huang, Jiwei Gao, Ziqing Chen, Hao Shi, Juan Yuan, Huanhuan L. Cui, Chun-Nan Yeh, Robert Bränström, Catharina Larsson, Shuijie Li, Weng-Onn Lui   +10 more
doaj   +1 more source

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report

Journal of Medical Case Reports, 2011
Introduction Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors.
Kang Yoon-Koo
doaj   +1 more source

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

PLoS ONE, 2011
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed
Jérome Kluza, Manel Jendoubi, Caroline Ballot, Abir Dammak, Aurélie Jonneaux, Thierry Idziorek, Sami Joha, Véronique Dauphin, Myriam Malet-Martino, Stéphane Balayssac, Patrice Maboudou, Gilbert Briand, Pierre Formstecher, Bruno Quesnel, Philippe Marchetti   +14 more
doaj   +1 more source

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Haematologica, 2016
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed.
Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, Dong-Wook Kim   +20 more
doaj   +1 more source

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Gastroenterology Research and Practice, 2014
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal ...
Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida   +3 more
doaj   +1 more source

Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.

PLoS ONE, 2021
BackgroundVascular endothelial dysfunction is an essential part of the pathophysiology of type 2 diabetes and its complications. In type 2 diabetes, endothelial dysfunction is characterized by reduced insulin signaling and increased transendothelial ...
Camiel V J Box, Amandeep K Sandhu, Alexander H Turaihi, Pan Xiaoké, Geesje Dallinga-Thie, Jurjan Aman, Etto C Eringa   +6 more
doaj   +1 more source

Imatinib-Induced Psoriasis

Turkish Journal of Hematology, 2013
Imatinib is a signal transduction regulator that selectively inhibits the tyrosine kinase family, including bcr-abl and c-kit, and the platelet-derived growth factor (PDGF) receptor. It is currently the fi rst-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients [1].
Atalay, Figen, Kizilkilic, Ebru, Ada, R. Simin   +2 more
openaire   +4 more sources

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis

Frontiers in Systems Neuroscience, 2022
Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-α, -β, stem cell factor receptor (c-KIT), and BCR-ABL.
Megan Perkins, Beatrice M. Girard, Susan E. Campbell, Grant W. Hennig, Margaret A. Vizzard   +4 more
doaj   +1 more source

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Drug Design, Development and Therapy, 2022
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology ...
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM   +4 more
doaj